Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice for hormone-receptor-positive early breast cancer in postmenopausal women. Extending treatment with an aromatase inhibitor to 10 years may further reduce the risk of breast-cancer recurrence.We conducted a double-blind, placebo-controlled trial to assess the effect of the extended use of letrozole for an additional 5...